# 'Modern' dose distributions: what should we not forget?

Uulke van der Heide



#### Using CT to delineate the target volume

Example: prostate cancer

Standard: homogeneous dose to entire prostate



## Using multi-parametric imaging to differentiate dose inside the target volume

Example: prostate cancer

Standard: homogeneous dose to entire prostate

New: escalate dose at location of highest tumor burden





## Using multi-parametric imaging to differentiate dose inside the target volume

Example: prostate cancer

Standard: homogeneous dose to entire prostate

New: escalate dose at location of highest tumor burden

What about uncertainties?





#### **Uncertainties to consider**

### The radiotherapy chain



beam data

17 steps with a lot of room for errors



Courtesy Marcel van Herk

#### **Uncertainties to consider: target definition**

#### **Delineation uncertainties**

Prostate

Tumor



Nyholm et al. 2013; Radiat Oncol.



Steenbergen et al. 2015; Radiat Oncol.





#### **Towards a probabilistic definition of target volumes**





Express uncertainty in the target definition by probabilities

'Gross Tumor Volume' becomes 'Gross Tumor Map'



#### **Towards a probabilistic definition of target volumes**





Express uncertainty in the target definition by probabilities Include likelihood of extra-capsular disease

'Clinical Tumor Volume' becomes 'Clinical Tumor Map'

#### **Uncertainties to consider: positioning uncertainties**

Organ motion

Inter-fraction motion



Courtesy Marcel van Herk



#### **Uncertainties to consider: positioning uncertainties**

Organ motion Inter-fraction motion Intra-fraction motion



Nederveen et al. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):206-14





#### Adapt each fraction to the changing shape of the target



**Treatment Assessment** 



#### **MRI-guided radiotherapy**



ICRU report 97: MRI-Guided Radiation Therapy Using MRI-Linear Accelerators



#### **Uncertainties in on-line adaptive radiotherapy**

	ATP	ATR	
Simulation/treatment planning			
Match uncertainty planning CT and planning MRI	S	S	
Contouring uncertainty	S	S	
On-line treatment			
Match uncertainty planning CT and adaptation MRI	R	R	
Contouring uncertainty	-	-	
Geometrical uncertainties of the linac	S/R	S/R	
Intra-fraction motion	R	R	

#### **Uncertainties in on-line adaptive radiotherapy**

	ATP	ATR	ATS
Simulation/treatment planning			
Match uncertainty planning CT and planning MRI	S	S	-
Contouring uncertainty	S	S	-
On-line treatment			
Match uncertainty planning CT and adaptation MRI	R	R	-
Contouring uncertainty	-	-	R
Geometrical uncertainties of the linac	S/R	S/R	S/R
Intra-fraction motion	R	R	R

Systematic errors may become random in an on-line adaptive workflow

The dose gradient is described with  $\sigma_p = 3.2 \text{ mm}$ 90% of patients receives a minimum dose of  $\geq$  95% of the prescribed dose



The dose gradient is described with  $\sigma_p = 3.2 \text{ mm}$ 90% of patients receives a minimum dose of  $\geq$  95% of the prescribed dose

#### 10% of patients must not receive the prescribed dose



The dose gradient is described with  $\sigma_p = 3.2 \text{ mm}$ 90% of patients receives a minimum dose of  $\geq$  95% of the prescribed dose

### 10% of patients must not receive the prescribed dose (but not a whole lot less)



#### Destination

ICR The Institute of Cancer Research





Low-intermediate risk prostate cancer 5 fractions GTV: isotoxic boost up to 45 Gy CTV (prostate): 30 Gy





#### **Planning study**

23 patients with intermediate risk prostate cancer treated on Elekta Unity 1.5T T2w MRIs available for adaptation and post-treatment in 5 fractions GTV: 45 Gy, CTV 30 Gy PTV = 0 mm



Time interval between adaptation- and post-MRI mean 18 min [14-27]



**Dose coverage of the GTV** 

D98% > 40 Gy in 90% of fractions

When correcting intra-fraction motion > 2 mm: D98% > 42 Gy in 90% of fractions

Analysis per fraction, renormalized to 5 fractions





**Dose coverage of the CTV** 

D98% > 29 Gy in 90% of fractions When correcting intra-fraction motion > 2 mm: D98% > 30 Gy in 90% of fractions Analysis per fraction, renormalized to 5 fractions

adaptation-MRI

post-MRI

VETHERLANDS CANCER INSTITUTE ANTONI VAN LEEUWENHOEK

'gated' <2 mm

The dose gradient is described with  $\sigma_p = 3.2 \text{ mm}$ 90% of patients receives minimally the prescribed dose

Tumor cells are homogeneously distributed in the target volume



#### Can we estimate the tumor load in the CTV?

61 prostatectomy specimen

84% of patients had multifocal disease (median 3 foci)

32% of foci smaller than 5 mm diameter

Contribution of small foci to total tumor load 2%

Hollmann et al. Radiother Oncol. 2015 Apr;115(1):96-100

Gleason Pattern 3 Gleason Pattern 4







#### **Implications for PTV margins**

For CTV the inhomogeneous distribution of tumor cells is not considered in the classical margin recipes

There is a high probability that the underdosed volume contains no cancer at all

The dose doesn't fall to zero



#### Modern dose distributions: what we shouldn't forget

To express uncertainty, a probabilistic target definition is desirable With on-line adaptive radiotherapy, positioning errors are substantially reduced With ultra-hypofractionation, (almost) all errors become systematic The tumor cells are not homogeneously distributed inside the CTV. This has profound implications for the required PTV margin



#### Acknowledgements

#### NKI

Thijs Dassen Ben Neijndorff Peter de Ruiter Thyrza Jagt Tomas Janssen Floris Pos

**KWF Elekta** 

Royal Marsden Hospital/ICR Alison Tree Sunnybrook Danny Vesprini Elekta John Christodouleas University of Wisconsin Robert Jeraj Peter Ferjančič

